NFKB1 and melanoma: The compounds under study were initially characterized by their capacity to interact with adaptor molecules of the NF-κB pathway, a transcription factor involved in oncogenic processes (31), and were tested in the NCI-60 cell line panel that contained 8 melanoma cell lines.